• In August 2026, Biohaven Ltd. announced a global licensing and collaboration agreement giving SK Biopharmaceuticals exclusive worldwide rights to its Kv7 ion channel platform, including opakalim, with up to US$795 million in upfront and milestone payments plus tiered royalties.
• A key feature of the deal is that SK Biopharmaceuticals will fund future Kv7 program costs and assume up to US$245 million in existing milestone and royalty obligations, materially easing Biohaven’s development burden while preserving a royalty stream.
• We’ll now examine how this capital infusion and transfer of Kv7 development costs could shape Biohaven’s investment narrative in the months ahead.

The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Biohaven's Investment Narrative?

To own Biohaven today, you have to believe its neurology and immunology pipeline can ultimately justify heavy losses, zero current revenue, and a very large price to book multiple. The new SK Biopharmaceuticals deal slots directly into that thesis, converting part of the Kv7 platform into US$400 million of near-term cash and future royalties while shifting about US$245 million of potential obligations off Biohaven’s books, which helps address earlier concerns around a cash runway of less than a year. In the near term, the key catalysts still center on late stage data readouts, especially opakalim in focal epilepsy and progress in the MoDE/TRAP programs, but Biohaven is now less dependent on raising capital around those events. The flip side is that long term value from opakalim is now partially shared with SK, and execution risk across the rest of the pipeline remains high.

However, investors also need to consider how dilution and ongoing losses could still affect returns.

Biohaven's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$21.73 to US$72.63, underlining how far apart individual views are on Biohaven’s prospects. Against that backdrop, the recent Kv7 licensing deal, while easing near term funding pressure, still leaves you exposed to binary clinical outcomes and an unprofitable profile, which could drive sharp swings in sentiment and valuation. If you are weighing Biohaven, it may help to compare these differing views with your own tolerance for clinical and financing uncertainty.

Explore 2 other fair value estimates on Biohaven - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Biohaven research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
• Our free Biohaven research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biohaven's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.